| Autor: |
Sworder, B. J., Alig, S. K., Shukla, N., Garofalo, A., Macaulay, C. W., Esfahani, M. Shahrokh, Olsen, M. N., Hamilton, J., Hosoya, H., Hamilton, M. P., Spiegel, J. Y., Baird, J. H., Carleton, M., Younes, S. F., Schroers‐Martin, J. G., Liu, C. L., Natkunam, Y., Majzner, R. G., Mackall, C. L., Miklos, D. B. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p214-216, 3p |
| Abstrakt: |
B Conclusions: b Detection of ctDNA MRD using PhasED-Seq is prognostic for outcomes in rrLBCL patients undergoing CAR19 therapy, and has superior performance compared to CAPP-Seq and PET/CT. B Introduction: b Over half of relapsed/refractory large B-cell lymphoma (rrLBCL) patients receiving anti-CD19 chimeric antigen receptor (CAR19) T-cells experience subsequent relapse. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text